HMBD-001 + nab-paclitaxel + gemcitabine

**HMBD-001 + nab-paclitaxel + gemcitabine** is a combination therapy consisting of HMBD-001 (a monoclonal antibody targeting HER3), nab-paclitaxel (albumin-bound form of paclitaxel), and gemcitabine (a nucleoside analog). HMBD-001 is designed to block HER3 (receptor tyrosine protein kinase ERBB3), a protein that drives growth and treatment resistance in several cancers, including those with NRG1 fusions[1][3][5][7]. Nab-paclitaxel disrupts microtubule function by binding tubulin, and its albumin-bound form enhances delivery to tumor cells[4]. Gemcitabine is a cytidine analogue that inhibits DNA synthesis, resulting in cell death[2][4]. The combination is currently under clinical investigation for advanced HER3-positive solid tumors, including pancreatic cancer, with early evidence suggesting synergistic anti-tumor activity and tolerable toxicity[1][3][4][5][6][8]. HMBD-001 is developed by Hummingbird Bioscience[3][5][7]. Nab-paclitaxel and gemcitabine are marketed and manufactured by multiple companies for cancer indications, including Bristol Myers Squibb (nab-paclitaxel as Abraxane)[4].

Other names

HMBD-001 plus nab-paclitaxel and gemcitabineHMBD001 plus nab-paclitaxel and gemcitabineHMBD 001 plus nab-paclitaxel and gemcitabineHMBD-001 + nab-P/Gem